MedTrace Logo

Efficacy and Safety Study of Norethindrone Acetate Transdermal Delivery System in Contraception

NCT01140217 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1659

Last updated 2013-09-19

No results posted yet for this study

Summary

The purpose of this study is to determine whether NEA TDS is effective in the prevention of pregnancy. The safety of this product will also be evaluated.

Conditions

  • Contraceptive Usage

Interventions

DRUG

Norethindrone Acetate

Norethindrone Acetate Transdermal Delivery System

Sponsors & Collaborators

  • Watson Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Kim E Caramelli, MS · Watson Pharmaceuticals, Inc.

Study Design

Allocation
NA
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-05-31
Primary Completion
2012-03-31
Completion
2012-03-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01140217 on ClinicalTrials.gov